In this the third and final segment from Grant Howard's interview with Dr. Harlan Waksal, he discusses his expectations for Acasti once it completes its Phase II study. He talks about Lovaza®'s and Amarin's billion dollar valuations and Acasti's potential for a similar valuation.
